Related Experiment Video
Updated: Jul 28, 2026
06:58
Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
Published on: June 25, 2016
Carbamazepine plus stiripentol: is polytherapy by design possible?
1Department of Psychology, University of Washington, Seattle 98195.
Epilepsia
|July 1, 1988
Summary
The combination of carbamazepine (CBZ) and stiripentol (STP) demonstrated synergistic effects in a monkey model, significantly reducing seizure spikes. This suggests polytherapy benefits may outweigh risks in epilepsy treatment.
Area of Science:
- Pharmacology
- Neuroscience
- Epileptology
Background:
- Epilepsy treatment often involves polytherapy, but drug interactions can pose challenges.
- Carbamazepine (CBZ) is a common antiepileptic drug.
- Stiripentol (STP) is another antiepileptic agent with a different mechanism of action.
Purpose of the Study:
- To investigate the synergistic effects of combining carbamazepine (CBZ) with stiripentol (STP) in an epilepsy model.
- To compare the electroencephalographic (EEG) effects of CBZ monotherapy versus CBZ + STP polytherapy.
Main Methods:
- An alumina-gel monkey model of epilepsy was used.
- The study involved five phases: baseline, CBZ monotherapy, CBZ + STP, CBZ monotherapy, and post-drug baseline.
- Interictal spikes were manually counted to assess EEG activity.
- Drug concentrations and the CBZ-epoxide/CBZ ratio were monitored.
Main Results:
- CBZ monotherapy increased interictal EEG spikes by 42% compared to baseline.
- The addition of STP to CBZ reduced spike rate by 39% compared to CBZ monotherapy.
- Removal of STP reversed the effect, increasing spike rate by 66%.
- The CBZ-epoxide/CBZ ratio decreased significantly with STP addition, indicating altered metabolism.
Conclusions:
- The combination of CBZ and STP exhibits synergistic anticonvulsant effects in this model.
- The findings suggest that the benefits of CBZ + STP polytherapy may outweigh the typical disadvantages.
- Pharmacodynamic interactions appear to explain the observed synergistic effects.
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:26Pharmaceutical Poisoning: Treatment Strategies
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications